NCT07292441

Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss

A Multicenter Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: Gan & Lee Pharmaceuticals. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18 Injection once every 4 weeks (Q4W) for 24 weeks on body weight. In this study, it is planned to include subjects who have participated in the original study and completed the study contents of the original protocol. All subjects will maintain a regular diet and exercise lifestyle during the study.

Conditions

• Overweight or Obesity

Interventions

Type	Name	Description
DRUG	GZR18 injection	Used as specified in the protocol
OTHER	Placebo	Administered the same volume as GZR18

Timeline

• Start date: 2026-01-22
• Primary completion: 2027-09-01
• Completion: 2027-10-01
• First posted: 2025-12-18
• Last updated: 2026-03-11

Locations

2 sites across 1 country: China